This company is one to watch. They have a patent for a mode of action that is applicable to SCN1A and SYNGAP1. At the 2018 AES they released impressive initial data around their studies on Dravet mice in partnership with a team from U. Michigan.
“Q-State Biosciences was birthed in 2014 when we realized that human stem cell models combined with all-optical electrophysiology and functional genomics enables us to find new drugs for devastating disorders of the nervous system and to find evidence that a particular drug may be effective for an individual patient.”
This company has an incredible team and is focusing on AAVs. We are hopeful they will put SynGAP1 in their pipeline.
Tevard Biosciences is developing novel gene therapy platforms to target Dravet Syndrome and other rare diseases with high unmet need. The company was founded in 2017 by Daniel Fischer and Warren Lammert, two parents of girls with Dravet Syndrome, and Harvey Lodish. Tevard’s SAB includes Bob Langer, David Liu, Lita Nelsen, Orrin Devinsky, and Ann Poduri. Source: https://labcentral.org/resident-companies/tevard
“Ovid Therapeutics is a biopharmaceutical company focused exclusively on developing impactful medicines for patients and families living with rare neurological disorders.”
“Through our dedication to innovation, quality, rigor and transparency, Swedish company Olink Proteomics provides outstanding products and services for human protein biomarker research. We help scientists get answers quickly and confidently through robust, multiplex biomarker analysis. Olink's immunoassay panels enable rapid, high-throughput analysis, with exceptional data quality and minimal sample consumption. Using just 1 µl of sample, 92 biomarkers are assayed simultaneously, with up to 96 samples run per panel. Our Proximity Extension Assay (PEA) technology enables this high level of multiplexing, as this dual recognition, DNA-coupled method provides exceptional readout specificity. Disease area-focused panels have both validated and exploratory biomarkers, selected in collaboration with leading experts, and our rigorous assay validation data is freely available. Choosing either ready-to-use kits or our Olink Analysis Service, customers get high quality data and rapid high-throughput analysis that makes the most effective use of their precious samples.”